You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CDK 4/6 inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Breast Cancer Trial in Lebanon (Fulvestrant, Neratinib, Alpelisib)

Not yet recruiting
  • Advanced Breast Cancer
  • Lebanon, New Hampshire
    Dartmouth Hitchcock Medical Center
Jun 28, 2023

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;

Recruiting
  • Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
  • dalpiciclib; fluvestrant; compound gossypol acetate tablets
  • Hangzhou, Zhejiang, China
    zhejiangCH
Nov 9, 2023

Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

Not yet recruiting
  • Estrogen-receptor-positive Breast Cancer
  • +3 more
  • elacestrant, palbociclib, abemaciclib, ribociclib
  • Chicago, Illinois
    Northwestern University
Sep 25, 2023

Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)

Not yet recruiting
  • Advanced HR+ HER2 Negative Breast Carcinoma
  • (CDK)4/6 inhibitor
  • (no location specified)
Sep 27, 2022

Cancer Trial in Boston (Abemaciclib)

Recruiting
  • Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 9, 2023

Breast Cancer Trial in Baltimore (Endocrine Therapy and a CDK 4/6 inhibitor)

Recruiting
  • Breast Cancer
  • Endocrine Therapy and a CDK 4/6 inhibitor
  • Baltimore, Maryland
    Johns Hopkins University
Jul 18, 2022

Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

Recruiting
  • Neurofibromatosis 1
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Breast Cancer Trial (RP-6306, Gemcitabine, Observation)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Jan 26, 2023

Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Breast Cancer Trial (Abemaciclib, Letrozole)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Nov 14, 2023

Breast Cancer Trial in Boston, Danvers (Ribociclib, Endocrine therapy)

Recruiting
  • Breast Cancer
  • Boston, Massachusetts
  • +2 more
Jan 6, 2023

Advanced Breast Cancer Trial in Beijing (The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy

Recruiting
  • Advanced Breast Cancer
  • The combination of Dalpiciclib with physician-selected endocrine therapy
  • Chemotherapy selected by the physician
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
May 22, 2023

Metastatic Breast Cancer Trial (Elacestrant)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 24, 2022

CDK4/6 Inhibitors in Hormone Receptor-positive Advanced Breast

Not yet recruiting
  • Breast Cancer
  • CDK4/6 inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Apr 5, 2023

Liposarcoma, Dedifferentiated Trial in New York (SPH4336)

Not yet recruiting
  • Liposarcoma, Dedifferentiated
  • New York, New York
    Columbia University Medical Center
Oct 13, 2022

HR+/HER2- Advanced Breast Cancer Trial in Beijing (Dalpiciclib, Chidamide)

Not yet recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Oct 17, 2022

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

Not yet recruiting
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • (no location specified)
Sep 26, 2023

Breast Cancer Trial in Guangzhou (Tucidinostat, Capecitabine, Endocrine Therapy)

Recruiting
  • Breast Cancer
  • Guangzhou, Gangdong, China
    Shusen Wang
Nov 1, 2022

Advanced Breast Cancer Trial in Seoul (Olaparib, Fulvestrant)

Not yet recruiting
  • Advanced Breast Cancer
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Sep 12, 2022

Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)

Recruiting
  • Locally Advanced Breast Cancer
  • Hormone Receptor Positiveļ¼ŒHER2-negative Breast Cancer
  • Jinan, Shandong, China
    Breast Cancer Center, Shandong Cancer Hospital and Institute
Apr 11, 2023

Breast Cancer, Advanced Breast Cancer Trial in Shanghai (Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and

Not yet recruiting
  • Breast Cancer
  • Advanced Breast Cancer
  • Everolimus 10 mg
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 14, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Dalpiciclib Isetionate Tablets, Camrelizumab
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023

Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)

Not yet recruiting
  • Metastatic Breast Cancer
  • +3 more
  • (no location specified)
Aug 18, 2022

Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)

Recruiting
  • Lung Cancer Squamous Cell
  • +3 more
  • Boston, Massachusetts
  • +2 more
Jan 9, 2023